Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 2—February 2019
Perspective

International Biological Reference Preparations for Epidemic Infectious Diseases

Tommy RamplingComments to Author , Mark Page, and Peter Horby
Author affiliations: Hospital for Tropical Diseases, London, UK (T. Rampling); National Institute for Biological Standards and Control, Potter’s Bar, UK (M. Page); University of Oxford, Oxford, UK (P. Horby)

Main Article

Table 2

Revised list of World Health Organization priority diseases, February 2018*

Disease or pathogen Current development status of international reference preparations
Crimean-Congo hemorrhagic fever
None available. Source material required.
Ebola virus disease and Marburg virus disease
Ebola virus antibody and NA IRPs available. VP40 antigen in development. No other filovirus IRPs available. Source material required.
Lassa fever
None available. Source material required.
MERS-CoV and SARS
Antibody and NA IRPs in development for MERS-CoV. Additional source material required.
Nipah virus and related henipavirus diseases
None available. Source material required.
Rift Valley fever
None available. Source material required.
Zika
NA and antibody IRPs available.
Disease X†
Not applicable.
Diseases or pathogens considered for inclusion on priority pathogen list and under annual review
Arenavirus hemorrhagic fevers other than Lassa fever None available. Source material required.
Chikungunya None available.
Highly pathogenic coronavirus diseases other than MERS-CoV and SARS None available. Source material required.
Emergent nonpolio enteroviruses (including EV71, D68) EV71 antibody IRP available. No other nonpolio enterovirus IRPs available. Source material required.
Severe fever with thrombocytopenia syndrome None available. Source material required.

*EV, enterovirus; IRP, international reference preparation; MERS-CoV, Middle East respiratory syndrome coronavirus; NA, nucleic acid; SARS, severe acute respiratory syndrome; VP, virus protein.
†Any disease identified before the next review by using the blueprint decision instrument will be included in the list.

Main Article

Page created: January 18, 2019
Page updated: January 18, 2019
Page reviewed: January 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external